The Tourette Syndrome Drug Race: Why SciSparc Is Running Last

THE HEADLINE name-drops Yale to lend gravitas. The substance reveals something less flattering. On July 15th, NeuroThera Labs, a majority-owned subsidiary of SciSparc Ltd (Nasdaq: SPRC), announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based drug candidate for Tourette syndrome, at three sites including the Yale Child Study Center. The press release is careful with its claims. The numbers are less careful with the company's prospects.

Tourette syndrome is a chronic neurodevelopmental disorder characterised by involuntary motor and vocal tics, most often appearing before the age of ten. The standard pharmacological treatments are FDA-approved antipsychotics - haloperidol, pimozide, and aripiprazole - which blunt dopamine signalling through D2 receptors and carry side effects ranging from weight gain to tardive dyskinesia, a potentially irreversible movement disorder. The unmet need is real. The question is whether SCI-110 can fill it, or whether it is the financial limb of a company that has already burned through most of its credibility.

SCI-110 combines dronabinol, a synthetic cannabinoid, with palmitoylethanolamide, an endocannabinoid-like compound. The theory is that the pairing reduces tics while mitigating the side effects typically associated with cannabinoids. In a Phase IIa study conducted at Yale University, the drug produced an average tic reduction of 21% on the Yale Global Tic Severity Scale, the standard measurement tool. Nearly 40% of participants saw reductions above 25%. The safety profile was clean. That is the foundation the company is building its Phase IIb programme on.

It is not a sturdy one. The 21% average reduction falls well short of the efficacy benchmarks that have earned cannabinoid drugs regulatory approval. Epidiolex, the most prominent precedent, received FDA approval for severe childhood epilepsies based on a 44% median seizure reduction in pivotal trials. SCI-110 also targets an indication where the evidence base for cannabinoids is rated Grade C - the weakest category - by clinical guidelines. A cross-over Phase IIb design will help. Patients serve as their own controls, which increases statistical power. But the design cannot conjure efficacy that the molecule may not possess.

To be sure, the responder subgroup - those patients exceeding a 25% tic reduction - suggests that SCI-110 may work better for certain phenotypes than the average implies. A precision-enrolment strategy in Phase IIb, pre-screening for the baseline characteristics of Phase IIa responders, could produce a statistically meaningful readout without requiring a large sample. That would be the smarter path. Whether NeuroThera has the clinical operations bandwidth to execute it is another matter. The parent company employs three people.

That leads to the constraint that matters most. SciSparc has a market capitalisation of $3.86m, $4.6m in cash, and an annual cash burn of roughly $4.1m. It has approximately 13 months of runway. The stock has shed 87% of its value over the past 52 weeks. Shares outstanding have expanded by 303% in one year, the dilutive consequence of repeated financing rounds for a company that generated $856,000 in revenue in 2025 against losses of $12.2m. Institutional ownership sits at 0.5%. The market has spoken; the only question is whether it has spoken too gently.

The competitive landscape adds urgency. Emalex Biosciences, a rival developer, has already completed a Phase III trial of ecopipam, a first-in-class dopamine D1 receptor antagonist for Tourette syndrome. Published results in the Journal of the American Medical Association: Neurology in May 2026 showed a 50% reduction in relapse risk compared with placebo in paediatric patients, with a tolerable side-effect profile. Emalex is now seeking FDA approval and has already secured an Expanded Access Programme, allowing physicians to prescribe the drug to patients outside the trial. Ecopipam targets a different receptor than the approved antipsychotics, which means fewer movement-related side effects. It will almost certainly become the new standard of care once approved.

That timing is disquieting for SCI-110. When a competitor demonstrates clear efficacy with a novel mechanism, it reshapes what regulators and payers consider the acceptable bar. SCI-110's Phase IIb data will need to look substantially better than 21% to persuade anyone that it deserves a place beside ecopipam rather than in its shadow. The Tourette syndrome drug market, meanwhile, is not the white space the press release implies. GlobalData estimated the global Tourette therapy market at approximately $248m in 2024 and projected it to fall to $84m by 2030, as off-label treatments lose ground to patent-protected generics and as ecopipam - when approved - cannibalises the older drugs that currently dominate prescribing. The addressable revenue for a late entrant with modest efficacy is narrower than the headline suggests.

The choice to open the first Phase IIb site in Germany rather than the United States is defensible but revealing. European academic centres, including Hannover Medical School, have accumulated experience with cannabis-derived investigational compounds through national compassionate-use and early-access frameworks that predate America's Schedule I research restrictions. The infrastructure reduces site-initiation friction. It also signals that the company is optimising for speed of enrolment rather than building an American evidence base that would strengthen an eventual FDA submission. A rational priority for a company on a clock.

The deeper problem is not trial design or site selection. It is the arithmetic of a micro-cap biotech with a single asset, no revenue, and a competitor a phase ahead. SciSparc's shareholders face the familiar trilemma of distressed clinical companies: wait for data that may not arrive in time, accept further dilution to fund the wait, or sell at a price that reflects the most likely outcome. None of the three is palatable.

For investors, the relevant risk is not whether SCI-110 might work in a subgroup of adult patients. It is whether a company with months of cash can survive long enough to find out. The Yale name on the press release is real. So is the Yale data behind the 21% figure. But the structural evidence - the financial position, the competitive timeline, the market size - points to a different conclusion. SCI-110 is a long shot with a shrinking runway and a rival that has already crossed the finish line.